Serina's SER-252, a sustained-release apomorphine formulation, advanced to Phase 1b Cohort 2 after demonstrating pharmacokinetic consistency and exploratory motor improvements in eight Parkinson's patients. The independent safety review supports continued dose escalation with topline data expected in H1 2027.
Key Points
- Sustained apomorphine exposure achieved pharmacokinetic profile as designed
- Exploratory clinical measures showed motor improvement in individual patients
- Independent Safety Monitoring Committee cleared dose escalation progression
Longevity Analysis
Parkinson's disease involves progressive dopaminergic neuronal loss that impairs motor control and quality of life. Sustained dopaminergic stimulation through continuous drug delivery addresses a fundamental mechanistic problem—the body's inability to maintain stable neurotransmitter levels—rather than treating symptoms episodically. If SER-252 sustains dopaminergic tone while reducing administration frequency, it may improve both motor stability and adherence, two factors linked to slower functional decline in Parkinson's progression. The trial's advancement on safety grounds suggests the formulation tolerates continuous delivery, a prerequisite for any sustained therapeutic to reach long-term efficacy endpoints.
Original published by LT Wire.